X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs126367-   
Low Rs61265-   
Sales per share (Unadj.) Rs301.8109.1-  
Earnings per share (Unadj.) Rs-24.9-27.5-  
Cash flow per share (Unadj.) Rs2.5-22.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.385.7-  
Shares outstanding (eoy) m12.34168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.7%   
Avg P/E ratio x-3.8-11.5 32.7%  
P/CF ratio (eoy) x36.7-13.9 -265.2%  
Price / Book Value ratio x0.33.7 8.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15453,291 2.2%   
No. of employees `0000.94.3 21.5%   
Total wages/salary Rs m3933,345 11.8%   
Avg. sales/employee Rs Th4,026.14,290.3 93.8%   
Avg. wages/employee Rs Th425.0779.1 54.5%   
Avg. net profit/employee Rs Th-331.8-1,081.1 30.7%   
INCOME DATA
Net Sales Rs m3,72418,418 20.2%  
Other income Rs m23129 17.4%   
Total revenues Rs m3,74718,547 20.2%   
Gross profit Rs m395-3,192 -12.4%  
Depreciation Rs m338795 42.6%   
Interest Rs m354499 71.0%   
Profit before tax Rs m-275-4,357 6.3%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32272 11.6%   
Profit after tax Rs m-307-4,641 6.6%  
Gross profit margin %10.6-17.3 -61.2%  
Effective tax rate %-11.5-6.2 183.7%   
Net profit margin %-8.2-25.2 32.7%  
BALANCE SHEET DATA
Current assets Rs m2,63813,490 19.6%   
Current liabilities Rs m2,3057,590 30.4%   
Net working cap to sales %8.932.0 27.9%  
Current ratio x1.11.8 64.4%  
Inventory Days Days135111 122.1%  
Debtors Days Days46124 37.4%  
Net fixed assets Rs m4,8717,863 61.9%   
Share capital Rs m12386 144.3%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,61914,456 25.0%   
Long term debt Rs m1,3745,080 27.1%   
Total assets Rs m7,50927,309 27.5%  
Interest coverage x0.2-7.7 -2.9%   
Debt to equity ratio x0.40.4 108.1%  
Sales to assets ratio x0.50.7 73.5%   
Return on assets %0.6-15.2 -4.2%  
Return on equity %-8.5-32.1 26.4%  
Return on capital %1.6-19.8 -8.0%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m5141,572 32.7%  
From Investments Rs m-123-483 25.5%  
From Financial Activity Rs m-3874,611 -8.4%  
Net Cashflow Rs m45,700 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.06 Rs / ZAR

Compare VENUS REMEDIES With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: UNICHEM LAB  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  DR. DATSONS LABS  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 21, 2018 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS